Abstract
About this talk
The interaction between retinol-binding protein 4 (RBP4) and transthyretin (TTR) is implicated in the pathogenesis of diseases such as macular degeneration and transthyretin amyloidosis. Our study identifies novel kinetic stabilizers of the TTR tetramer, offering a therapeutic strategy to inhibit this critical interaction. Through a robust screening of chemical libraries, we isolated compounds that effectively stabilize TTR tetramers. These stabilizers were shown to disrupt the RBP4-TTR interaction, a novel approach in managing these diseases. Our analyses confirm the efficacy of these stabilizers in reducing TTR aggregation. This research opens avenues for developing treatments for macular degeneration, transthyretin amyloidosis, and their related comorbidities, potentially impacting patient care for these age-related conditions.
Audience Take-Away:
- Understanding of TTR Amyloidosis and Macular Degeneration: The audience will gain a comprehensive overview of these diseases, their impact on health, and the role of the RBP4-TTR interaction in their pathogenesis
- Innovative Therapeutic Approaches: Insight into the identification and role of Transthyretin (TTR) tetramer kinetic stabilizers in disrupting RBP4-TTR interactions, a novel therapeutic strategy
- Scientific Methodology and Discovery: Insights into the methodology used for identifying these stabilizers, including chemical screening and various assays
- Clinical Implications: The efficacy and potential therapeutic impact of these stabilizers in treating TTR amyloidosis and macular degeneration
- Future Research Directions: Future directions for research and potential clinical applications of these finding
Speaker
About the speaker
